Esbriet to be removed from prescription drug lists for Individual Exchange plans
Effective April 1, 2023, Esbriet®¹ will no longer be on our Individual Exchange plans² prescription drug lists (PDLs). We’ll continue to cover the generic equivalent, pirfenidone, on our specialty tier.
This applies to all states except Texas and Louisiana, where the change will become effective Jan. 1, 2024.
If you have questions, please contact your provider advocate.
¹A medication used to treat idiopathic pulmonary fibrosis.
²Also referred to as UnitedHealthcare Individual & Family ACA Marketplace plans.